Payment overview · 2025
General Payments
$1,821.84
48 reported records · 9 companies
Healthcare provider profile · identity verified
Zu Yu Chen, D.O
Allopathic & Osteopathic Physicians|Family Medicine · FLUSHING, NY · NPI 1023413747
Verified facts
What the public records show
CMS Open Payments records show Zu Yu Chen, D.O received $1,821.84 in general payments during 2025 across 48 reported records.
Amgen Inc. accounted for 48.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Prolia, Qulipta, Rybelsus, Shingrix, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Ubrelvy by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Prolia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Synjardy by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Eliquis by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $885.86 | 48.6% | 11 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $268.32 | 14.7% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $209.33 | 11.5% | 14 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $125.00 | 6.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $105.15 | 5.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $70.32 | 3.9% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $66.00 | 3.6% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $60.16 | 3.3% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $31.70 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,821.84 | 48 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $577.49 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $209.33 | 14 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $196.72 | 12 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $192.50 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $183.37 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $105.15 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $70.32 | 3 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $66.00 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $31.70 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $30.16 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $30.16 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $18.20 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 90 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 47 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 77 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 31 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 41 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
117 | 24 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
41 | 13 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
47 | 37 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
90 | 26 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
108 | 21 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
31 | 29 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
31 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
77 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1411 | 292 |
| Amlodipine Besylate | Amlodipine Besylate | 447 | 106 |
| Losartan Potassium | Losartan Potassium | 439 | 108 |
| Vascepa | Icosapent Ethyl | 322 | 68 |
| Tamsulosin Hcl | Tamsulosin Hcl | 318 | 66 |
| Raloxifene Hcl | Raloxifene Hcl | 278 | 57 |
| Fluticasone Propionate | Fluticasone Propionate | 265 | 66 |
| Clopidogrel | Clopidogrel Bisulfate | 249 | 54 |
| Diclofenac Epolamine | Diclofenac Epolamine | 248 | 58 |
| Lisinopril | Lisinopril | 215 | 52 |
| Gabapentin | Gabapentin | 213 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 204 | 50 |
| Metformin Hcl | Metformin Hcl | 192 | 50 |
| Omeprazole | Omeprazole | 182 | 70 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 170 | 45 |
| Finasteride | Finasteride | 166 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 163 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 142 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 133 | 50 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 132 | 59 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 125 | 38 |
| Linzess | Linaclotide | 117 | 24 |
| Levothyroxine Sodium | Levothyroxine Sodium | 114 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 112 | 21 |
| Hydrocortisone | Hydrocortisone | 109 | 29 |
| Synjardy | Empagliflozin/Metformin Hcl | 108 | 21 |
| Alendronate Sodium | Alendronate Sodium | 107 | 28 |
| Ammonium Lactate | Ammonium Lactate | 105 | 44 |
| Folic Acid | Folic Acid | 105 | 27 |
| Allopurinol | Allopurinol | 104 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 100 | 44 |
| Trazodone Hcl | Trazodone Hcl | 93 | 27 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 90 | 35 |
| Jardiance | Empagliflozin | 90 | 26 |
| Azithromycin | Azithromycin | 89 | 77 |
| Meclizine Hcl | Meclizine Hcl | 82 | 38 |
| Terconazole | Terconazole | 81 | 22 |
| Naproxen | Naproxen | 80 | 50 |
| Atenolol | Atenolol | 77 | 11 |
| Rybelsus | Semaglutide | 77 | 12 |
| Metformin Hcl Er | Metformin Hcl | 74 | 15 |
| Clobetasol Propionate | Clobetasol Propionate | 73 | 45 |
| Famotidine | Famotidine | 69 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 67 | 16 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 65 | 35 |
| Ezetimibe | Ezetimibe | 64 | 15 |
| Meloxicam | Meloxicam | 64 | 24 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 63 | 15 |
| Amoxicillin | Amoxicillin | 61 | 51 |
| Montelukast Sodium | Montelukast Sodium | 61 | 13 |
| Donepezil Hcl | Donepezil Hcl | 59 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 59 | 12 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 56 | 19 |
| Enalapril Maleate | Enalapril Maleate | 55 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 55 | 11 |
| Mometasone Furoate | Mometasone Furoate | 49 | 24 |
| Repatha Sureclick | Evolocumab | 48 | 14 |
| Prolia | Denosumab | 47 | 37 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 45 | 23 |
| Ketoconazole | Ketoconazole | 45 | 17 |
| Celecoxib | Celecoxib | 43 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 43 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | 16 |
| Restasis | Cyclosporine | 43 | 16 |
| Qulipta | Atogepant | 41 | suppressed |
| Ubrelvy | Ubrogepant | 41 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 36 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 39 | suppressed |
| Lidocaine | Lidocaine | 39 | 13 |
| Procto-Med Hc | Hydrocortisone | 39 | 12 |
| Ursodiol | Ursodiol | 39 | suppressed |
| Creon | Lipase/Protease/Amylase | 38 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 38 | suppressed |
| Simvastatin | Simvastatin | 38 | 11 |
| Synthroid | Levothyroxine Sodium | 38 | suppressed |
| Valsartan | Valsartan | 37 | suppressed |
| Bepotastine Besilate | Bepotastine Besilate | 36 | 14 |
| Mupirocin | Mupirocin | 36 | 30 |
| Nebivolol Hcl | Nebivolol Hcl | 36 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 34 | 13 |
| Nifedipine Er | Nifedipine | 34 | suppressed |
| Eliquis | Apixaban | 33 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 32 | 24 |
| Carvedilol | Carvedilol | 32 | suppressed |
| Mirtazapine | Mirtazapine | 32 | suppressed |
| Ranolazine Er | Ranolazine | 32 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 31 | 29 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 31 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 30 | suppressed |
| Primidone | Primidone | 30 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 30 | 22 |
| Nitroglycerin | Nitroglycerin | 29 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 28 | suppressed |
| Loperamide | Loperamide Hcl | 28 | 20 |
| Zenpep | Lipase/Protease/Amylase | 28 | suppressed |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 27 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 25 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 25 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 24 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 23 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | 15 |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 21 | 13 |
| Glipizide Er | Glipizide | 21 | suppressed |
| Nexium | Esomeprazole Magnesium | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 19 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 18 | 12 |
| Erythromycin | Erythromycin Base | 18 | 16 |
| Ibuprofen | Ibuprofen | 17 | 17 |
| Glipizide | Glipizide | 16 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 16 | suppressed |
| Repatha Pushtronex | Evolocumab | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Furosemide | Furosemide | 15 | suppressed |
| Ozempic | Semaglutide | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 14 | 14 |
| Lubiprostone | Lubiprostone | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Cyclosporine | Cyclosporine | 13 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 13 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Potassium Chloride | Potassium Chloride | 12 | suppressed |
| Proctozone-Hc | Hydrocortisone | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Fluocinonide | Fluocinonide | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Multaq | Dronedarone Hcl | 11 | suppressed |
| Nateglinide | Nateglinide | 11 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,821.84 · 48 records | Amgen Inc. | ABRYSVO, Auvelity, COBENFY, EVENITY, JARDIANCE, OTEZLA, Ozempic, PROLIA, QULIPTA, REPATHA, Rybelsus, SHINGRIX, UBRELVY | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error